Jci_page_head_homepage_01 Jci_page_head_homepage_02
Dwight Cordero, Ralph Marcucio, Diane Hu, William Gaffield, Minal Tapadia, Jill A. Helms
Published in Volume 114, Issue 4
J Clin Invest. 2004; 114(4):485–494 doi:10.1172/JCI19596
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 3

Cyclopamine elicits a spectrum of HPE defects. (A) Cyclopamine administration at St. 22 has no discernible effect on craniofacial development relative to (B) HBC (and untreated) controls. Note equivalent size of the premaxilla (pm) in cyclopamine and control embryos. (C) If cyclopamine is delivered at St. 20, the premaxilla fails to extend; compare dotted line with that in (D). (E) When cyclopamine is administered at St. 17, the distal tip of the upper beak fails to form (arrow), the midface is hypoplastic, and embryos are microcephalic. Proximal facial structures and the mandible (mn) are unaffected compared with controls (F). (G) Cyclopamine exposure at St. 15 results in a compressed mediolateral facial axis (red arrow). Note single telencephalic (te) bulge and a severely reduced frontonasal primordium (fnp), which causes the nasal pits (np) to approximate in the midline and the eyes to deviate medially; control is shown in (H). The dorsoventral facial axis is also distorted, as indicated by the proximity of Rathke’s pouch to the frontonasal primordium, which effectively eliminates the roof of the oral cavity. The maxillary and mandibular primordia are either absent or greatly reduced. (I) Cyclopamine delivery at St. 10 causes an arrest in midline growth, resulting in fused telencephalic vesicles and nasal pits, which create a proboscis. Midline entities such as the frontonasal primordium fail to develop compared with HBC controls (J). The majority of embryos die within 24 hours of treatment. Scale bars: 1.0 mm (AF, I, and J); 2.0 mm (G and H). tx, treatment.